TESARO Inc. and Genentech entered into a clinical collaboration to evaluate the combination of the PD-L1 antibody atezolizumab (Tecentriq), the MEK inhibitor cobimetinib (Cotellic) and TESARO’s PARP inhibitor Zejula (niraparib) in patients with platinum-sensitive ovarian cancer.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe